Blood markers of brain cell damage higher over short term in COVID-19 patients than...
Patients hospitalized for COVID-19 had higher levels over the short term of blood proteins known to rise with neurological damage than non-COVID-19 patients diagnosed with Alzheimer's disease, a new study finds.
Importantly, the current report,...
Expert Available to Discuss Alzheimer’s Medication in the Wake of Medicare Decision
Los Angeles (January 12, 2022) -- WHAT:Following Medicare’s decision today about paying for a new Alzheimer’s disease treatment only in limited circumstances, Zaldy Tan, MD, MPH, a highly respected memory and geriatric medicine specialist at...
MD Anderson Research Highlights for January 12, 2022
Newswise — The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include an...
Evidence of damage and also neuroprotective processes long before symptoms of dementia manifest —...
Long before the onset of dementia, there is evidence for increased activity of the brain's immune system. Researchers from DZNE and the University Hospital Bonn (UKB) come to this conclusion based on a study...
Florida State researchers identify link that plays a role in regulating neuropsychiatric brain disorders
By: McKenzie Harris | Published: January 12, 2022 | 2:44 pm | SHARE: Newswise — Florida State University researchers have identified a link between two key parts of the brain that play significant roles...
Alzheimer’s Treatments on the Horizon
Newswise — Los Angeles (January 11, 2022) --Treatments for Alzheimer’s disease—a condition affecting more than 5 million Americans—have been slow to progress. But in mid-2021, the Food and Drug Administration (FDA) approved aducanumab—marketed under...